Cure Today

Sac-TMT Combo Shows Benefit in Advanced Lung Cancer Treatment

Sac-TMT combined with Keytruda significantly improves progression-free survival in PD-L1-positive advanced non-small cell lung cancer. The OptiTROP-Lung05 study is the first phase 3 trial of an ...
The Manila Times

Head-to-Head Real-World Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer

Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), comparing cadonilimab plus chemot ...
Business Wire

PD-1 x VEGF and PD-L1 x VEGF Bispecific Antibodies Market Research 2025: Ivonescimab has Set the Bar for Competitors - Business, Pipeline and Competitor Analysis ...

DUBLIN--(BUSINESS WIRE)--The "PD-1 x VEGF and PD-L1 x VEGF Bispecific Antibodies: A Business, Pipeline And Competitor Analysis From An Industry Perspective" report has been added to ResearchAndMarkets ...
Targeted Oncology

Sacituzumab Govitecan and Pembrolizumab: A New Frontline for mTNBC

A groundbreaking study reveals that sacituzumab govitecan and pembrolizumab significantly enhance survival in untreated metastatic triple-negative breast cancer patients.
Zacks Investment Research on MSN

Is BMY's deep pipeline the key to its next growth phase?

Bristol Myers Squibb BMY highlighted the potential of its deep and promising pipeline at the 44th Annual J.P. Morgan ...

Global Development Accelerates: Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Granted Fast Track Designation by FDA

Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, stated: ...
Medindia

Head-to-Head Real-World Data: Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer

Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO G I), comparing cadonilimab ...